17β-HSD Inhibitor

17β-HSD Inhibitors (118):

Cat. No.	Product Name	Effect	Purity

HY-148814

BI-3231	Inhibitor	99.83%
BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC₅₀s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases.

HY-19903

ASP-9521	Inhibitor	≥98.0%
ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC₅₀ of 11 nM for human AKR1C3.

HY-138557

AKR1C3-IN-4	Inhibitor	99.77%
AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.

HY-107379

AKR1C3-IN-1	Inhibitor	98.23%
AKR1C3-IN-1 is a potent, highly selective inhibitor of AKR1C3, with an IC₅₀ of 13 nM.

HY-155035

S07-1066	Inhibitor	99.48%
S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells.

HY-161979

HSD17B13-IN-103	Inhibitor
HSD17B13-IN-103 (Compound 44) is a HSD17B13 inhibitor. HSD17B13-IN-103 can be used in the study of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

HY-W267205

3-Acetyl-7-Hydroxycoumarin	Inhibitor
3-Acetyl-7-Hydroxycoumarin (Compound 2) is a high selective 17-beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor. 3-Acetyl-7-Hydroxycoumarin shows a significant improvement of the inhibitory potency, with 57% inhibition of 17β-HSD1 at 6 μM. 3-Acetyl-7-Hydroxycoumarin is promising for research of hormone-dependent diseases, such as breast cancer and endometriosis.

HY-156735

HSD17B13-IN-2	Inhibitor	99.72%
HSD17B13-IN-2 (compound 1) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-2 has cell experimental activity.

HY-156736

HSD17B13-IN-3	Inhibitor	99.78%
HSD17B13-IN-3 (compound 2) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-3 does not have cell experimental activity.

HY-103394

TC HSD 21	Inhibitor	99.14%
TC HSD 21 is a potent 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor with an IC₅₀ of 14 nM. TC HSD 21 shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors.

HY-161227

HSD17B13-IN-43	Inhibitor	99.68%
HSD17B13-IN-43 (11) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-157627

HSD17B13-IN-9	Inhibitor	99.92%
HSD17B13-IN-9 (252) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC₅₀ of 0.01 μM for 50 nM HSD17B13. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-161212

HSD17B13-IN-8	Inhibitor	99.97%
HSD17B13-IN-8 (1) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with IC₅₀ values of <0.1 μM for Estradiol and <1 μM for LTB3. Used in NAFLD (Nonalcoholic fatty liver diseases) research.

HY-128145

HSD17B13-IN-41	Inhibitor
HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.

HY-159525

Linustedastatum	Inhibitor
Linustedastatum (Linustedastat) is a hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) inhibitor.

HY-163243

HSD17B13-IN-29	Inhibitor
HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-163249

HSD17B13-IN-49	Inhibitor
HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-161229

HSD17B13-IN-69	Inhibitor
HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).

HY-157708

HSD17B13-IN-67	Inhibitor
HSD17B13-IN-67 (Compound 677) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-67 can be used for research on liver diseases or metabolic disorders.

HY-157722

HSD17B13-IN-73	Inhibitor
HSD17B13-IN-73 (Compound 85) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-73 can be used for research on liver diseases or metabolic disorders.

Name
Email *

	Sorry, but the email address you supplied was invalid.